$1.62
-0.07 (-4.14%)
Open$1.64
Previous Close$1.69
Day High$1.69
Day Low$1.58
52W High$5.30
52W Low$1.41
Volume—
Avg Volume143.8K
Market Cap4.67M
P/E Ratio—
EPS$1.07
SectorBiotechnology
Analyst Ratings
Strong Sell
7 analysts
Price Target
+1,667.3% upside
Current
$1.62
$1.62
Target
$28.63
$28.63
$25.08
$28.63 avg
$44.18
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 270.2K | 590.1K | 3.56M |
| Net Income | -4,668,325 | -9,175,567 | 452.9K |
| Profit Margin | -1,727.8% | -1,641.4% | 12.7% |
| EBITDA | -4,409,355 | -9,148,039 | 509.0K |
| Free Cash Flow | — | — | 445.4K |
| Rev Growth | -54.2% | -54.2% | +0.2% |
| Debt/Equity | — | — | 0.51 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |